Corporate Action
Zydus Lifesciences Completes Assertio Holdings Acquisition, Finalizes Merger Through Zara Merger Sub
NSE
ZYDUSLIFE
BSE
532321
Zydus Lifesciences Limited has completed the acquisition of Nasdaq-listed Assertio Holdings Inc. through the merger of Zara Merger Sub Inc., its wholly owned acquisition subsidiary, into Assertio. Following completion of the transaction, Assertio has become a wholly owned subsidiary of Zydus and its common stock has ceased trading on the Nasdaq Global Market.
PRICE-SENSITIVE TRIGGER
Event: Completion of acquisition and merger of Assertio Holdings Inc.
Type: Corporate Action | Acquisition Completion
Impact: Positive
Immediate Effect:Â The completion of the merger has resulted in Assertio Holdings becoming a wholly owned subsidiary of Zydus Lifesciences. The acquisition of all outstanding Assertio shares has been finalized, giving Zydus full ownership and control of the company’s operations and product portfolio. Following the transaction, Assertio’s common stock has ceased trading on the Nasdaq Global Market, formally integrating the business into Zydus’ global pharmaceutical operations.
Key Metrics:
- Acquisition Consideration: USD 166.33 million
- Offer Price: USD 23.50 per share
- Target Company: Assertio Holdings Inc.
- Geography: United States
- Adjusted CY2025 Revenue of ROLVEDON® Business: USD 68.23 million
- Ownership Post Transaction: 100%
Highlight:
- Transaction Value: USD 166.33 million all-cash acquisition completed, giving Zydus full ownership of Assertio Holdings and its oncology-focused commercial portfolio.
What Happened ?
Zydus Lifesciences informed stock exchanges that Zara Merger Sub Inc., a step-down wholly owned acquisition subsidiary of the company, has merged into Assertio Holdings Inc. As a result, Assertio has become a wholly owned subsidiary of Zydus Lifesciences.
The merger completes the acquisition of all outstanding common shares of Assertio. Following completion, Assertio’s common stock is no longer listed or traded on the Nasdaq Global Market. The transaction was consummated on June 16, 2026.
Key Details
Acquisition Completion and Strategic Expansion in U.S. Specialty Pharmaceuticals:
- Zara Merger Sub Inc. was incorporated on April 24, 2026 as an acquisition vehicle.
- Assertio Holdings Inc. is a Nasdaq-listed specialty pharmaceutical company headquartered in Delaware, USA.
- Manufacturing activities Assertio has established commercialization, marketing and distribution capabilities focused on oncology products.supported by Nibe’s integrated defence manufacturing complex in Shirdi, Maharashtra.
- The acquisition provides Zydus access to Assertio’s oncology-supportive care franchise.
- Assertio’s flagship product, ROLVEDON® (eflapegrastim-xnst), is approved by the USFDA.
- ROLVEDON® is used to prevent febrile neutropenia in adult cancer patients undergoing myelosuppressive chemotherapy.
- The product is administered once per chemotherapy cycle, serving the oncology supportive-care market.
- The merger structure enabled Zydus to acquire all outstanding shares and make Assertio a wholly owned subsidiary.
Note:
- The acquisition strengthens Zydus Lifesciences’ presence in the U.S. specialty pharmaceutical market while adding a commercial oncology asset with established revenue generation and distribution capabilities.
Risk Analysis
Summary:
- While the transaction expands Zydus’ specialty pharmaceutical footprint in the United States, future value creation will depend on successful integration of Assertio’s operations and sustained performance of its oncology portfolio.
Key Risks:
- Integration and operational execution risk following acquisition.
- Dependence on continued commercial performance of ROLVEDON®.
- Regulatory and reimbursement dynamics in the U.S. pharmaceutical market.
- Competitive pressures within oncology-supportive care therapies.
- Potential challenges in realizing strategic synergies.
Worst Case Scenario:
- Failure to maintain product growth, regulatory setbacks, or integration inefficiencies could limit the expected commercial and financial benefits from the acquisition.
Risk Level: Medium
Company Commentary
- Zara Merger Sub Inc. has merged into Assertio Holdings Inc.
- Assertio has become a wholly owned subsidiary of Zydus Lifesciences.
- Acquisition of all outstanding common shares has been completed.
- Assertio shares are no longer listed or traded on Nasdaq Global Market.
- The merger and acquisition transaction has been fully consummated as of June 16, 2026.
- The transaction was executed to acquire full ownership and control of Assertio.
Official Exchange Filing: Zydus Lifesciences Limited
